

Vyepti[®] (eptinezumab)

DOSING AND ADMINISTRATION

Vyepti[®] is indicated for the preventive treatment of migraine in adults¹



HOW TO DILUTE

- ⊘ Vyepti requires dilution before administration.¹
- ⊘ Vyepti is a clear to slightly opalescent, colourless to brownish-yellow solution.¹
- ⊘ Inspect vial visually for particulate matter and discoloration before use – do not administer if the Vyepti contains visible particulate matter or is cloudy or discoloured.¹

RECOMMENDED DOSE

1 To prepare Vyepti 100 mg¹

- Withdraw 1 mL of Vyepti from a single-dose vial using a sterile needle and syringe.
- Inject the 1 mL Vyepti into a 100 mL bag of 0.9% sodium chloride injection.
- Do not use any other diluents.

To prepare Vyepti 300 mg dose¹

- Withdraw 1 mL from each of three single-dose vials using a sterile needle and syringe.
- Inject the 3 mL Vyepti into a 100 mL bag of 0.9% sodium chloride injection.
- Do not use any other diluents.



Use appropriate aseptic technique when preparing Vyepti solution for intravenous (IV) infusion.

2 Gently invert the bag to mix completely. Do not shake.¹

3 After dilution, Vyepti must be infused as soon as practicable and within 8 hours. Until infusion, the solution can be kept at room temperature (20–25°C) or refrigerated (2–8°C). Do not freeze. If refrigerated, allow the solution to come to room temperature before infusing.¹

- ⊘ Vyepti single-dose vials contain no preservative; discard unused product in the vial.¹

HOW TO ADMINISTER INFUSIONS

- ⊘ **DO NOT** administer Vyepti as an IV push or bolus injection.¹
- ⊘ **DO NOT** mix Vyepti with any other medications or administer any other medication through the infusion set.¹

Step 1 Use an IV infusion set with a 0.2 or 0.22 µm in-line or add-on sterile filter to administer the diluted Vyepti solution intravenously.¹

Step 2 Infuse over 30 minutes to administer the whole dose.¹


Step 3 When complete, flush the line with 20 mL of 0.9% sodium chloride solution. The treating physician should observe or monitor patients during and after the infusion in accordance with normal clinical practice.¹



One 30-minute infusion every 12 weeks¹

POST-INFUSION

Schedule three-monthly (12-weekly) appointments for ongoing treatment.¹



SCAN TO LEARN MORE



Vyepti[®] PBS Information: This product is not listed on the PBS.

Vyepti[®] is indicated for the preventive treatment of migraine in adults.¹

Please review the full Approved Product Information for Vyepti before prescribing. Product Information is available by calling Lundbeck on 1300 721 277 or scanning this QR Code.

▼ This medicinal product is subject to additional monitoring in Australia. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse events at www.tga.gov.au/reporting-problems.

Reference: 1. Vyepti[®] Australian Approved Product Information.

© Vyepti is a registered trademark of H. Lundbeck A/S and used under licence.
Lundbeck Australia Pty Ltd, ABN 86 070 094 290, Ground Floor, 1 Innovation Road, North Ryde NSW 2113.
Ph: +61 2 8669 1000, Fax: +61 2 8669 1090, Medical Information: 1300 721 277.
LUNDV001 January 2022 AU-VYEP-0044 905595

